Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-13 23:47 | 2025-08-12 | XERS | Xeris Biopharma Holdings, Inc. | HALKUFF DAWN | Director | SELL | $7.28 | 42,500 | $309,226 | 115,000 |
| 2025-08-13 23:40 | 2025-08-12 | AMRX | Amneal Pharmaceuticals Inc. | Shah Nikita | Officer | SELL | $9.04 | 50,000 | $452,000 | 338,929 |
| 2025-08-13 23:39 | 2025-08-12 | AMRX | Amneal Pharmaceuticals Inc. | Daly Jason B. | Officer | SELL | $9.05 | 22,000 | $199,100 | 10,606 |
| 2025-08-14 01:00 | 2025-08-11 | LGVN | Longeveron Inc. | Locklear Lisa | Officer | BUY | $0.00 | 11,766 | $0 | 250,964 |
| 2025-08-14 01:00 | 2025-08-11 | LGVN | Longeveron Inc. | Baluch Khoso | Director | BUY | $0.00 | 11,766 | $0 | 52,516 |
| 2025-08-13 20:58 | 2025-08-11 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | Officer | BUY | $0.04 | 1,056,064 | $42,243 | 5,256,094 |
| 2025-08-13 16:58 | 2025-08-11 | URGN | UroGen Pharma Ltd. | Schoenberg Mark | Officer | SELL | $17.69 | 10,000 | $176,900 | 148,229 |
| 2025-08-13 23:15 | 2025-08-13 | LLY | ELI LILLY & Co | Van Naarden Jacob | Officer | BUY | $647.36 | 1,000 | $647,360 | 20,562 |
| 2025-08-14 01:32 | 2025-08-11 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Shulman Joseph | Officer | OPT+S | $90.08 | 3,984 | $358,891 | 8,509 |
| 2025-08-14 01:08 | 2025-08-12 | VTRS | Viatris Inc | Smith Scott Andrew | Director, Officer | BUY | $9.99 | 22,000 | $219,740 | 314,807 |
| 2025-08-13 23:05 | 2025-08-07 | BIVI | BIOVIE INC. | DO CUONG V | Director, Officer | BUY | $0.00 | 5,000 | $0 | 9,992 |
| 2025-08-13 23:05 | 2025-08-11 | IRWD | IRONWOOD PHARMACEUTICALS INC | Gaskins Tammi L | Officer | SELL | $0.84 | 1,316 | $1,105 | 241,280 |
| 2025-08-13 23:05 | 2025-08-11 | IRWD | IRONWOOD PHARMACEUTICALS INC | John Minardo | Officer | SELL | $0.84 | 7,754 | $6,513 | 400,378 |
| 2025-08-13 23:05 | 2025-08-11 | IRWD | IRONWOOD PHARMACEUTICALS INC | Silver Ronald | Officer | SELL | $0.84 | 2,846 | $2,391 | 276,809 |
| 2025-08-13 23:05 | 2025-08-11 | IRWD | IRONWOOD PHARMACEUTICALS INC | Martini Gregory S. | Officer | SELL | $0.84 | 1,265 | $1,063 | 182,545 |
| 2025-08-14 01:51 | 2025-08-11 | BHC | Bausch Health Companies Inc. | Paulson John | Director | BUY | $6.56 | 3,243,049 | $21,267,591 | 36,034,751 |
| 2025-08-13 23:22 | 2025-08-12 | EBS | Emergent BioSolutions Inc. | DeGolyer Donald W | Director | SELL | $8.65 | 7,844 | $67,831 | 137,659 |
| 2025-08-13 23:49 | 2025-08-11 | NAMS | NewAmsterdam Pharma Co N.V. | Topper James N | Director | BUY | $23.98 | 471 | $11,294 | 3,026,604 |
| 2025-08-14 01:03 | 2025-08-11 | ALDX | Aldeyra Therapeutics Inc. | Machatha Stephen | Officer | SELL | $5.15 | 22,073 | $113,713 | 221,799 |
| 2025-08-14 04:10 | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Director, Officer | SELL | $10.43 | 797 | $8,313 | 34,828 |
| 2025-08-14 03:00 | 2025-08-13 | WVE | Wave Life Sciences Ltd. | HENRY CHRISTIAN O | Director | SELL | $8.81 | 9,670 | $85,193 | 29,645 |
| 2025-08-13 23:38 | 2025-08-12 | AMRX | Amneal Pharmaceuticals Inc. | BOYER ANDREW S | Officer | SELL | $9.05 | 33,436 | $302,596 | 256,670 |
| 2025-08-14 00:33 | 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca | Director | OPT+S | $355.32 | 46,463 | $16,509,033 | 461,044 |
| 2025-08-14 01:18 | 2025-08-13 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Director | OPT+S | $370.24 | 129,172 | $47,825,145 | 187,164 |
| 2025-08-14 00:45 | 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Director | OPT+S | $355.31 | 46,808 | $16,631,388 | 187,164 |
| 2025-08-13 00:02 | 2025-08-08 | HRTX | HERON THERAPEUTICS, INC. /DE/ | Morgan Adam | Director | BUY | $1.50 | 1,766,546 | $2,649,819 | 8,753,290 |
| 2025-08-12 23:16 | 2025-08-11 | LLY | ELI LILLY & Co | Yuffa Ilya | Officer | SELL | $627.01 | 1,250 | $783,763 | 26,260 |
| 2025-08-13 00:04 | 2025-08-08 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | SELL | $14.03 | 3,847 | $53,988 | 108,999 |
| 2025-08-12 23:20 | 2025-08-12 | LLY | ELI LILLY & Co | Skovronsky Daniel | Officer | BUY | $634.41 | 1,000 | $634,405 | 137,660 |
| 2025-08-12 23:45 | 2025-08-08 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer | SELL | $34.01 | 4,096 | $139,305 | 16,908 |
| 2025-08-12 23:45 | 2025-08-08 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $34.69 | 100,000 | $3,468,970 | 536,962 |
| 2025-08-13 01:00 | 2025-08-08 | HRTX | HERON THERAPEUTICS, INC. /DE/ | Rubric Capital Management LP | 10% owner | BUY | $1.50 | 2,387,225 | $3,580,838 | 29,100,728 |
| 2025-08-12 19:30 | 2025-08-11 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | Officer | BUY | $0.04 | 500,000 | $19,500 | 4,200,030 |
| 2025-08-12 19:27 | 2025-08-08 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | Officer | BUY | $0.04 | 500,000 | $20,000 | 3,700,030 |
| 2025-08-12 23:45 | 2025-08-08 | ZLAB | Zai Lab Ltd | Amado Rafael | Officer | SELL | $35.00 | 3,000 | $105,000 | 42,178 |
| 2025-08-13 02:57 | 2025-08-11 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | Director, Officer | OPT+S | $62.00 | 40,000 | $2,480,000 | 138,641 |
| 2025-08-12 14:00 | 2025-08-08 | ITRM | Iterum Therapeutics plc | Dunne Michael W. | Director | BUY | $0.72 | 15,000 | $10,854 | 235,001 |
| 2025-08-12 23:23 | 2025-08-12 | LLY | ELI LILLY & Co | Ricks David A | Director, Officer | BUY | $644.77 | 1,632 | $1,052,263 | 546,601 |
| 2025-08-12 23:24 | 2025-08-08 | AGIO | Agios Pharmaceuticals Inc. | Goff Brian | Director, Officer | OPT+S | $36.67 | 11,085 | $406,487 | 123,528 |
| 2025-08-13 03:32 | 2025-08-12 | AKRO | Akero Therapeutics, Inc. | Henderson Jane | Director | OPT+S | $47.46 | 3,000 | $142,371 | 9,398 |
| 2025-08-12 23:17 | 2025-08-12 | LLY | ELI LILLY & Co | Fyrwald J Erik | Director | BUY | $642.33 | 1,565 | $1,005,242 | 74,578 |
| 2025-08-13 00:18 | 2025-08-08 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Freund John Gordon | Director | SELL | $34.36 | 11,659 | $400,641 | 23,129 |
| 2025-08-12 23:19 | 2025-08-12 | LLY | ELI LILLY & Co | Sulzberger Gabrielle | Director | BUY | $641.18 | 117 | $75,018 | 2,703 |
| 2025-08-13 03:00 | 2025-08-11 | MIRM | Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC | Officer | OPT+S | $0.00 | 8,000 | $0 | 28,236 |
| 2025-08-13 02:06 | 2025-08-08 | BBIO | BridgeBio Pharma, Inc. | HOMCY CHARLES J | Director | SELL | $46.37 | 300,000 | $13,912,440 | 916,674 |
| 2025-08-12 23:02 | 2025-08-08 | ANAB | AnaptysBio Inc. | RENTON HOLLINGS | Director | OPT+S | $19.62 | 10,231 | $200,714 | 4,965 |
| 2025-08-13 02:22 | 2025-08-11 | CORT | CORCEPT THERAPEUTICS INC | Swisher Daniel N JR | Director | OPT+S | $72.30 | 2,200 | $159,060 | 0 |
| 2025-08-13 02:19 | 2025-08-08 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $71.77 | 35,007 | $2,512,452 | 5,487 |
| 2025-08-12 00:53 | 2025-08-08 | ABT | Abbott Laboratories | Boudreau Philip P | Officer | SELL | $134.55 | 5,550 | $746,758 | 51,003 |
| 2025-08-12 01:29 | 2025-08-07 | BBIO | BridgeBio Pharma, Inc. | Apuli Maricel | Officer | SELL | $45.44 | 1,000 | $45,440 | 141,859 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.